LLYX241220P16000
- 1.25
- 0.000.00%
Defiance Daily Target 2X Long LLY ETF Newsroom
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
US Stock Outlook | Is the unemployment rate in the USA showing warning signs? Societe Generale warns: there will be a risk of recession next year; AI chip stocks are soaring in pre-market, Broadcom has risen over 17% after earnings.
Meta has released a new AI model that will enhance the Metaverse experience; with multiple Bullish factors combined, Taiwan Semiconductor rose over 2% in pre-market trading; Eli Lilly and Co's Mounjaro has replaced Novo-Nordisk A/S's Wegovy, becoming the new favorite weight loss drug in the United Kingdom.
Trump rings the opening bell for the NYSE: The stock market is everything, and significant actions will be taken regarding Cryptos.
On Thursday, Donald Trump rang the opening bell at the NYSE. He emphasized the importance of the stock market, stating that the stock market is everything, and plans to take significant actions regarding Cryptos, lower the corporate tax rate to 15%, and increase Petroleum Extraction to alleviate the current inflationary pressures.
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
"Person of the Year" Trump rings the opening bell at the NYSE, emphasizing that "the stock market is everything."
On December 12, the elected President Trump was named Time Magazine's Person of the Year for 2024, ringing the opening bell at the NYSE that day; Trump rang the bell with the CEO of ICE and the CEO of Time Magazine, along with the president of the NYSE, while the CEOs of companies such as Goldman Sachs and Citigroup were present; Trump promised an "unprecedented economy," planned to increase oil drilling to reduce inflation, and committed to lowering the corporate tax rate to 15%.
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients
'Eli Lilly to Sell Zepbound Through Telehealth Company Ro' - Barron's
Eli Lilly Unusual Options Activity
BofA Restarts Coverage of 11 Large-cap Biopharmas
Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts
What's Going On With Eli Lilly Stock On Tuesday?
Market-Moving News for December 10th
Eli Lilly Analyst Ratings
As Eli Lilly Shares Gain Over 35% YTD, Drugmaker Announces $15B Share Buyback Program And Boosts Dividend By 15%
Eli Lilly Reports Results From Phase 3 BRUIN CLL-321 Trial Evaluating Pirtobrutinib; Study's Primary Endpoint Of Progression-Free Survival Was Met At Primary Analysis
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
BioAge Stock Craters 75% on Obesity Drug Study Update
Lilly Tops Morgan Stanley's Biopharma Pick List for 2025